These observations pointed to the potential possibility of treatment with atacicept or APRIL antagonistic monoclonal antibodies (if considered to be evaluated in future clinical trials) in B-lymphoma and SLE patients with observed TACI receptor expression. Here, TNFSF13 is linked to systemic lupus erythematosus.